Axillary Hyperhidrosis Drug Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

1 RESEARCH SCOPE

1.1 Research Product Definition

1.2 Research Segmentation

1.2.1 Product Type

1.2.2 Main product Type of Major Players

1.3 Demand Overview

1.4 Research Methodology

2 GLOBAL AXILLARY HYPERHIDROSIS DRUG INDUSTRY

2.1 Summary about Axillary Hyperhidrosis Drug Industry

2.2 Axillary Hyperhidrosis Drug Market Trends

2.2.1 Axillary Hyperhidrosis Drug Production & Consumption Trends

2.2.2 Axillary Hyperhidrosis Drug Demand Structure Trends

2.3 Axillary Hyperhidrosis Drug Cost & Price

3 MARKET DYNAMICS

3.1 Manufacturing & Purchasing Behavior in 2020

3.2 Market Development under the Impact of COVID-19

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunity

3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

4.1 Region Segmentation (2017 to 2021f)

4.1.1 North America (U.S., Canada and Mexico)

4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)

4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)

4.1.4 South America (Brazil,, Argentina, Rest of Latin America)

4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)

4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 Botulinum ToxinA

4.2.2 Glycopyrrolate

4.2.3 Glycopyrronium Tosylate

4.2.4 Others

4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 Clinic

4.3.2 Hospital

4.3.3 Home Care

5 NORTH AMERICA MARKET SEGMENT

5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 Botulinum ToxinA

5.2.2 Glycopyrrolate

5.2.3 Glycopyrronium Tosylate

5.2.4 Others

5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 Clinic

5.3.2 Hospital

5.3.3 Home Care

5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

6.1.2 UK

6.1.3 France

6.1.4 Italy

6.1.5 Rest of Europe

6.2 Product Type Segmentation (2017 to 2021f)

6.2.1 Botulinum ToxinA

6.2.2 Glycopyrrolate

6.2.3 Glycopyrronium Tosylate

6.2.4 Others

6.3 Consumption Segmentation (2017 to 2021f)

6.3.1 Clinic

6.3.2 Hospital

6.3.3 Home Care

6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

7.1 Region Segmentation (2017 to 2021f)

7.1.1 China

7.1.2 India

7.1.3 Japan

7.1.4 South Korea

7.1.5 Southeast Asia

7.1.6 Australia

7.1.7 Rest of Asia Pacific

7.2 Product Type Segmentation (2017 to 2021f)

7.2.1 Botulinum ToxinA

7.2.2 Glycopyrrolate

7.2.3 Glycopyrronium Tosylate

7.2.4 Others

7.3 Consumption Segmentation (2017 to 2021f)

7.3.1 Clinic

7.3.2 Hospital

7.3.3 Home Care

7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

8.1 Region Segmentation (2017 to 2021f)

8.1.1 Brazil

8.1.2 Argentina

8.1.3 Rest of Latin America

8.2 Product Type Segmentation (2017 to 2021f)

8.2.1 Botulinum ToxinA

8.2.2 Glycopyrrolate

8.2.3 Glycopyrronium Tosylate

8.2.4 Others

8.3 Consumption Segmentation (2017 to 2021f)

8.3.1 Clinic

8.3.2 Hospital

8.3.3 Home Care

8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

9.1 Region Segmentation (2017 to 2021f)

9.1.1 GCC

9.1.2 North Africa

9.1.3 South Africa

9.1.4 Rest of Middle East and Africa

9.2 Product Type Segmentation (2017 to 2021f)

9.2.1 Botulinum ToxinA

9.2.2 Glycopyrrolate

9.2.3 Glycopyrronium Tosylate

9.2.4 Others

9.3 Consumption Segmentation (2017 to 2021f)

9.3.1 Clinic

9.3.2 Hospital

9.3.3 Home Care

9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

10.1 Brief Introduction of Major Players

10.1.1 Allergan Plc

10.1.2 Brickell Biotech Inc

10.1.3 Dermira Inc

10.1.4 Dr. August Wolff GmbH & Co KG Arzneimittle

10.1.5 GlaxoSmithKline Plc

10.1.6 TheraVida Inc

10.2 Axillary Hyperhidrosis Drug Sales Date of Major Players (2017-2020e)

10.2.1 Allergan Plc

10.2.2 Brickell Biotech Inc

10.2.3 Dermira Inc

10.2.4 Dr. August Wolff GmbH & Co KG Arzneimittle

10.2.5 GlaxoSmithKline Plc

10.2.6 TheraVida Inc

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

1.Table Axillary Hyperhidrosis Drug Product Type Overview

2.Table Axillary Hyperhidrosis Drug Product Type Market Share List

3.Table Axillary Hyperhidrosis Drug Product Type of Major Players

4.Table Brief Introduction of Allergan Plc

5.Table Brief Introduction of Brickell Biotech Inc

6.Table Brief Introduction of Dermira Inc

7.Table Brief Introduction of Dr. August Wolff GmbH & Co KG Arzneimittle

8.Table Brief Introduction of GlaxoSmithKline Plc

9.Table Brief Introduction of TheraVida Inc

10.Table Products & Services of Allergan Plc

11.Table Products & Services of Brickell Biotech Inc

12.Table Products & Services of Dermira Inc

13.Table Products & Services of Dr. August Wolff GmbH & Co KG Arzneimittle

14.Table Products & Services of GlaxoSmithKline Plc

15.Table Products & Services of TheraVida Inc

16.Table Market Distribution of Major Players

17.Table Global Major Players Sales Revenue (Million USD) 2017-2020e

18.Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e

19.Table Global Axillary Hyperhidrosis Drug Market Forecast (Million USD) by Region 2021f-2026f

20.Table Global Axillary Hyperhidrosis Drug Market Forecast (Million USD) Share by Region 2021f-2026f

21.Table Global Axillary Hyperhidrosis Drug Market Forecast (Million USD) by Demand 2021f-2026f

22.Table Global Axillary Hyperhidrosis Drug Market Forecast (Million USD) Share by Demand 2021f-2026f